ArticleInternational journal of women's health2025
Prognostic Factors and Role of Pelvic Lymphadenectomy in Patients with Uterine Sarcoma: A Multi-Center Population-Based Cohort Study.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The prognostic factors and impact of pelvic lymphadenectomy in uterine sarcomas remain unclear. This study aimed to investigate the prognostic factors and role of pelvic lymphadenectomy in uterine sarcoma. Methods: We analyzed the data of uterine sarcoma patients obtained from 17 centers through the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2021. After propensity score matching analysis, the characteristics of the patients who underwent pelvic lymphadenectomy and those who did not were compared. Univariate and multivariate analyses were performed on patient data before and after propensity score matching. Additionally, survival analyses were performed for different subgroups. Results: Multivariate COX regression analysis revealed that age, histology, tumor grade, and AJCC stage were correlated with prognosis (p < 0.001). Kaplan-Meier survival curve analysis showed that there was no significant difference in survival between the pelvic lymphadenectomy and non-pelvic lymphadenectomy groups (p=0.431). No statistically significant differences were observed in any of the subgroups analyzed, including age, histology, tumor size, tumor grade, stage, and marital status (p > 0.05). Conclusion: Patient age, histological type, grade, and stage were significantly associated with the prognosis of uterine sarcoma. Additionally, pelvic lymphadenectomy did not confer a survival benefit to patients with this disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.